Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance

Muhammad Usman Munir, Ayesha Ihsan, Ibrahim Javed, M. Tayyab Ansari, Sadia Z. Bajwa, Bukhari Syed Nasir Abbas, Arsalan Ahmed, M. Zubair Malik, Waheed S. Khan

Research output: Contribution to journalArticle

Abstract

Multidrug resistance (MDR) is a global threat posed by continuously evolving microbial resistance against currently available antimicrobial agents. In this study, we synthesized hydroxyapatite-based porous nanocarriers with pH-dependent biodegradation, using cefazolin (CFZ) as cargo drug against MDR E. coli, S. aureus, and P. aeruginosa. Oval-shaped porous hydroxyapatite nanoparticles (opHANPs) were synthesized via core-shell method. Field emission scanning electron microscopy revealed that the average length and width of opHANPs were found to be ∼90 and ∼110 nm, respectively with monodispersed size and morphology. The encapsulation efficiency (EE) of CFZ was observed to be dependent on the initial concentration of the drug (EE, 41.37-92.40% with 300-2000 μg/mL of CFZ). Brunauer-Emmett-Teller specific surface area and pore width of opHANPs were 166.73 m 2 /g and 3.3 nm, respectively, indicating hierarchal pore distribution. The pH-responsive drug release was observed from CFZ-loaded opHANPs (CFZ@opHANPs). An enhanced drug-releasing behavior was observed at lower pH (4.5, 2.5, and 1.5). The study of release kinetics revealed that at pH 7.4, drug release is due to anomalous diffusion, while at lower pH, the drug release followed fickian diffusion model. Cytotoxic and hemolytic studies showed biocompatibility of CFZ@opHANPs with HepG2 and red blood cells. The growth kinetic study and colony-forming unit assay showed the superior antibacterial potential of CFZ@opHANPs, in contrast to carrier or CFZ alone, against MDR E. coli, S. aureus, and P. aeruginosa strains.

Original languageEnglish
Pages (from-to)7524-7532
Number of pages9
JournalACS Omega
Volume4
Issue number4
DOIs
Publication statusPublished - 26 Feb 2019
Externally publishedYes

Fingerprint

Cefazolin
Durapatite
Hydroxyapatite
Nanostructures
Nanoparticles
Pharmaceutical Preparations
Encapsulation
Escherichia coli
Antimicrobial agents
Growth kinetics
Anti-Infective Agents
Biodegradation
Biocompatibility
Specific surface area
Field emission
Assays
Blood
Cells
Scanning electron microscopy

ASJC Scopus subject areas

  • Chemistry(all)
  • Chemical Engineering(all)

Cite this

Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance. / Munir, Muhammad Usman; Ihsan, Ayesha; Javed, Ibrahim; Ansari, M. Tayyab; Bajwa, Sadia Z.; Syed Nasir Abbas, Bukhari; Ahmed, Arsalan; Malik, M. Zubair; Khan, Waheed S.

In: ACS Omega, Vol. 4, No. 4, 26.02.2019, p. 7524-7532.

Research output: Contribution to journalArticle

Munir, MU, Ihsan, A, Javed, I, Ansari, MT, Bajwa, SZ, Syed Nasir Abbas, B, Ahmed, A, Malik, MZ & Khan, WS 2019, 'Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance', ACS Omega, vol. 4, no. 4, pp. 7524-7532. https://doi.org/10.1021/acsomega.9b00541
Munir, Muhammad Usman ; Ihsan, Ayesha ; Javed, Ibrahim ; Ansari, M. Tayyab ; Bajwa, Sadia Z. ; Syed Nasir Abbas, Bukhari ; Ahmed, Arsalan ; Malik, M. Zubair ; Khan, Waheed S. / Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance. In: ACS Omega. 2019 ; Vol. 4, No. 4. pp. 7524-7532.
@article{8b1a32b6170240f59183f7db45683e7c,
title = "Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance",
abstract = "Multidrug resistance (MDR) is a global threat posed by continuously evolving microbial resistance against currently available antimicrobial agents. In this study, we synthesized hydroxyapatite-based porous nanocarriers with pH-dependent biodegradation, using cefazolin (CFZ) as cargo drug against MDR E. coli, S. aureus, and P. aeruginosa. Oval-shaped porous hydroxyapatite nanoparticles (opHANPs) were synthesized via core-shell method. Field emission scanning electron microscopy revealed that the average length and width of opHANPs were found to be ∼90 and ∼110 nm, respectively with monodispersed size and morphology. The encapsulation efficiency (EE) of CFZ was observed to be dependent on the initial concentration of the drug (EE, 41.37-92.40{\%} with 300-2000 μg/mL of CFZ). Brunauer-Emmett-Teller specific surface area and pore width of opHANPs were 166.73 m 2 /g and 3.3 nm, respectively, indicating hierarchal pore distribution. The pH-responsive drug release was observed from CFZ-loaded opHANPs (CFZ@opHANPs). An enhanced drug-releasing behavior was observed at lower pH (4.5, 2.5, and 1.5). The study of release kinetics revealed that at pH 7.4, drug release is due to anomalous diffusion, while at lower pH, the drug release followed fickian diffusion model. Cytotoxic and hemolytic studies showed biocompatibility of CFZ@opHANPs with HepG2 and red blood cells. The growth kinetic study and colony-forming unit assay showed the superior antibacterial potential of CFZ@opHANPs, in contrast to carrier or CFZ alone, against MDR E. coli, S. aureus, and P. aeruginosa strains.",
author = "Munir, {Muhammad Usman} and Ayesha Ihsan and Ibrahim Javed and Ansari, {M. Tayyab} and Bajwa, {Sadia Z.} and {Syed Nasir Abbas}, Bukhari and Arsalan Ahmed and Malik, {M. Zubair} and Khan, {Waheed S.}",
year = "2019",
month = "2",
day = "26",
doi = "10.1021/acsomega.9b00541",
language = "English",
volume = "4",
pages = "7524--7532",
journal = "ACS Omega",
issn = "2470-1343",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Controllably Biodegradable Hydroxyapatite Nanostructures for Cefazolin Delivery against Antibacterial Resistance

AU - Munir, Muhammad Usman

AU - Ihsan, Ayesha

AU - Javed, Ibrahim

AU - Ansari, M. Tayyab

AU - Bajwa, Sadia Z.

AU - Syed Nasir Abbas, Bukhari

AU - Ahmed, Arsalan

AU - Malik, M. Zubair

AU - Khan, Waheed S.

PY - 2019/2/26

Y1 - 2019/2/26

N2 - Multidrug resistance (MDR) is a global threat posed by continuously evolving microbial resistance against currently available antimicrobial agents. In this study, we synthesized hydroxyapatite-based porous nanocarriers with pH-dependent biodegradation, using cefazolin (CFZ) as cargo drug against MDR E. coli, S. aureus, and P. aeruginosa. Oval-shaped porous hydroxyapatite nanoparticles (opHANPs) were synthesized via core-shell method. Field emission scanning electron microscopy revealed that the average length and width of opHANPs were found to be ∼90 and ∼110 nm, respectively with monodispersed size and morphology. The encapsulation efficiency (EE) of CFZ was observed to be dependent on the initial concentration of the drug (EE, 41.37-92.40% with 300-2000 μg/mL of CFZ). Brunauer-Emmett-Teller specific surface area and pore width of opHANPs were 166.73 m 2 /g and 3.3 nm, respectively, indicating hierarchal pore distribution. The pH-responsive drug release was observed from CFZ-loaded opHANPs (CFZ@opHANPs). An enhanced drug-releasing behavior was observed at lower pH (4.5, 2.5, and 1.5). The study of release kinetics revealed that at pH 7.4, drug release is due to anomalous diffusion, while at lower pH, the drug release followed fickian diffusion model. Cytotoxic and hemolytic studies showed biocompatibility of CFZ@opHANPs with HepG2 and red blood cells. The growth kinetic study and colony-forming unit assay showed the superior antibacterial potential of CFZ@opHANPs, in contrast to carrier or CFZ alone, against MDR E. coli, S. aureus, and P. aeruginosa strains.

AB - Multidrug resistance (MDR) is a global threat posed by continuously evolving microbial resistance against currently available antimicrobial agents. In this study, we synthesized hydroxyapatite-based porous nanocarriers with pH-dependent biodegradation, using cefazolin (CFZ) as cargo drug against MDR E. coli, S. aureus, and P. aeruginosa. Oval-shaped porous hydroxyapatite nanoparticles (opHANPs) were synthesized via core-shell method. Field emission scanning electron microscopy revealed that the average length and width of opHANPs were found to be ∼90 and ∼110 nm, respectively with monodispersed size and morphology. The encapsulation efficiency (EE) of CFZ was observed to be dependent on the initial concentration of the drug (EE, 41.37-92.40% with 300-2000 μg/mL of CFZ). Brunauer-Emmett-Teller specific surface area and pore width of opHANPs were 166.73 m 2 /g and 3.3 nm, respectively, indicating hierarchal pore distribution. The pH-responsive drug release was observed from CFZ-loaded opHANPs (CFZ@opHANPs). An enhanced drug-releasing behavior was observed at lower pH (4.5, 2.5, and 1.5). The study of release kinetics revealed that at pH 7.4, drug release is due to anomalous diffusion, while at lower pH, the drug release followed fickian diffusion model. Cytotoxic and hemolytic studies showed biocompatibility of CFZ@opHANPs with HepG2 and red blood cells. The growth kinetic study and colony-forming unit assay showed the superior antibacterial potential of CFZ@opHANPs, in contrast to carrier or CFZ alone, against MDR E. coli, S. aureus, and P. aeruginosa strains.

UR - http://www.scopus.com/inward/record.url?scp=85064980624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064980624&partnerID=8YFLogxK

U2 - 10.1021/acsomega.9b00541

DO - 10.1021/acsomega.9b00541

M3 - Article

VL - 4

SP - 7524

EP - 7532

JO - ACS Omega

JF - ACS Omega

SN - 2470-1343

IS - 4

ER -